Interpace Biosciences Overview
- Year Founded
-
1988
- Status
-
Public
- Employees
-
102
- Stock Symbol
-
IDXG
- Investments
-
9
- Share Price
-
$4.40
- (As of Friday Closing)
Interpace Biosciences General Information
Description
Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer based on clinical features. The company develops and commercializes genomic tests and related first-line assays that can personalize medicine and help improve patient diagnosis and management. Its clinical customers mainly consist of physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics. The various diagnostic tests offered by the company include ThyGeNEXT and ThyraMIRv2 for the detection of thyroid cancer.
Contact Information
Website
www.interpace.comCorporate Office
- 2001 Route 46 Waterview Plaza
- Suite 310
- Parsippany, NJ 07054
- United States
Corporate Office
- 2001 Route 46 Waterview Plaza
- Suite 310
- Parsippany, NJ 07054
- United States
Interpace Biosciences Stock Performance
As of 20-Nov-2026, Interpace Biosciences’s stock price is $4.40. Its current market cap is $26M with 5.9M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.40 | $4.60 | $4.15 - $12.00 | $26M | 5.9M | 2.88K | $25.46 |
Interpace Biosciences Financials Summary
As of 30-Sep-2026, Interpace Biosciences has a trailing 12-month revenue of $37.8M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 36,000 | 6,285 | 63,487 | 59,707 |
| Revenue | 37,761 | 38,728 | 46,926 | 40,036 |
| EBITDA | 1,562 | 4,763 | 8,357 | 4,890 |
| Net Income | 21,926 | 24,575 | 6,702 | 1,954 |
| Total Assets | 37,468 | 33,838 | 14,792 | 13,116 |
| Total Debt | 864 | 1,183 | 5,856 | 11,192 |
Interpace Biosciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Interpace Biosciences Comparisons
Industry
Financing
Details
Interpace Biosciences Competitors (26)
One of Interpace Biosciences’s 26 competitors is Biodesix, a Formerly VC-backed company based in Louisville, CO.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Biodesix | Formerly VC-backed | Louisville, CO | ||||
| NeoGenomics | Corporation | Fort Myers, FL | ||||
| Agendia | Venture Capital-Backed | Irvine, CA | ||||
| BioReference Health | Corporate Backed or Acquired | Elmwood Park, NJ | ||||
| PathGroup | Private Equity-Backed | Brentwood, TN |
Interpace Biosciences Patents
Interpace Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20180327856-A1 | Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions | Inactive | 04-Oct-2012 | ||
| EP-2771487-A1 | Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors | Inactive | 27-Oct-2011 | ||
| US-20190017122-A1 | Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors | Inactive | 27-Oct-2011 | ||
| US-10655184-B2 | Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease | Active | 13-Sep-2011 | ||
| US-20180066316-A1 | Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease | Active | 13-Sep-2011 | C12Q1/6886 |
Interpace Biosciences Signals
Interpace Biosciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Interpace Biosciences Investments & Acquisitions (9)
Interpace Biosciences’s most recent deal was a Merger/Acquisition with Cancer Genetics (Biopharma Services) for . The deal was made on 15-Jul-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Cancer Genetics (Biopharma Services) | 15-Jul-2019 | Merger/Acquisition | Laboratory Services (Healthcare) | ||
| Rosetta Genomics (Philadelphia Laboratory Equipments) | 15-Aug-2018 | Corporate Asset Purchase | Buildings and Property | ||
| RedPath Integrated Pathology | 03-Nov-2014 | Merger/Acquisition | Laboratory Services (Healthcare) | ||
| JS Genetics | 21-Aug-2014 | Merger/Acquisition | Laboratory Services (Healthcare) | ||
| Asuragen (MiRInform Thyroid and Pancreas Cancer Test Assets) | 13-Aug-2014 | Corporate Asset Purchase | Buildings and Property |
Interpace Biosciences ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Healthcare
Industry
Rank
Percentile
Medical Services
Subindustry
Rank
Percentile
Interpace Biosciences Exits (3)
Interpace Biosciences’s most recent exit was on 04-Nov-2010 from Group DCA. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Group DCA | 04-Nov-2010 | Completed |
|
||
| Xylos Corp | 10-Feb-2006 | Completed |
|
||
| Pharmakon (Biological Product) | 31-Aug-2004 | Merger/Acquisition | Completed |
Interpace Biosciences FAQs
-
When was Interpace Biosciences founded?
Interpace Biosciences was founded in 1988.
-
Where is Interpace Biosciences headquartered?
Interpace Biosciences is headquartered in Parsippany, NJ.
-
What is the size of Interpace Biosciences?
Interpace Biosciences has 102 total employees.
-
What industry is Interpace Biosciences in?
Interpace Biosciences’s primary industry is Laboratory Services (Healthcare).
-
Is Interpace Biosciences a private or public company?
Interpace Biosciences is a Public company.
-
What is Interpace Biosciences’s stock symbol?
The ticker symbol for Interpace Biosciences is IDXG.
-
What is the current stock price of Interpace Biosciences?
As of 20-Nov-2026 the stock price of Interpace Biosciences is $4.40.
-
What is the current market cap of Interpace Biosciences?
The current market capitalization of Interpace Biosciences is $26M.
-
What is Interpace Biosciences’s current revenue?
The trailing twelve month revenue for Interpace Biosciences is $37.8M.
-
Who are Interpace Biosciences’s competitors?
Biodesix, NeoGenomics, Agendia, BioReference Health, and PathGroup are some of the 26 competitors of Interpace Biosciences.
-
What is Interpace Biosciences’s annual earnings per share (EPS)?
Interpace Biosciences’s EPS for 12 months was $25.46.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process